nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—CA9—gall bladder—gallbladder cancer	0.0107	0.0386	CbGeAlD
Nilotinib—PDGFRA—gall bladder—gallbladder cancer	0.0086	0.0309	CbGeAlD
Nilotinib—MAPK8—epithelium—gallbladder cancer	0.00852	0.0306	CbGeAlD
Nilotinib—MAPK8—pancreas—gallbladder cancer	0.00759	0.0273	CbGeAlD
Nilotinib—TIE1—epithelium—gallbladder cancer	0.00739	0.0266	CbGeAlD
Nilotinib—KIT—gall bladder—gallbladder cancer	0.00688	0.0247	CbGeAlD
Nilotinib—PDGFRB—gall bladder—gallbladder cancer	0.00671	0.0241	CbGeAlD
Nilotinib—FRK—liver—gallbladder cancer	0.00633	0.0228	CbGeAlD
Nilotinib—MAPK14—epithelium—gallbladder cancer	0.00541	0.0195	CbGeAlD
Nilotinib—CDC42BPB—liver—gallbladder cancer	0.00534	0.0192	CbGeAlD
Nilotinib—EPHB4—epithelium—gallbladder cancer	0.00513	0.0184	CbGeAlD
Nilotinib—EPHA2—epithelium—gallbladder cancer	0.00503	0.0181	CbGeAlD
Nilotinib—TEK—epithelium—gallbladder cancer	0.00491	0.0177	CbGeAlD
Nilotinib—MAPK8—liver—gallbladder cancer	0.00483	0.0174	CbGeAlD
Nilotinib—BLK—lymph node—gallbladder cancer	0.00469	0.0168	CbGeAlD
Nilotinib—EPHB4—pancreas—gallbladder cancer	0.00457	0.0164	CbGeAlD
Nilotinib—EPHA2—pancreas—gallbladder cancer	0.00448	0.0161	CbGeAlD
Nilotinib—LYN—liver—gallbladder cancer	0.00446	0.016	CbGeAlD
Nilotinib—TEK—pancreas—gallbladder cancer	0.00437	0.0157	CbGeAlD
Nilotinib—TIE1—liver—gallbladder cancer	0.00419	0.0151	CbGeAlD
Nilotinib—MAPK11—lymph node—gallbladder cancer	0.00413	0.0148	CbGeAlD
Nilotinib—CDC42BPB—lymph node—gallbladder cancer	0.0041	0.0147	CbGeAlD
Nilotinib—CA2—gall bladder—gallbladder cancer	0.00408	0.0146	CbGeAlD
Nilotinib—BRAF—liver—gallbladder cancer	0.00402	0.0144	CbGeAlD
Nilotinib—EPHA3—lymph node—gallbladder cancer	0.00388	0.014	CbGeAlD
Nilotinib—MAPK8—lymph node—gallbladder cancer	0.0037	0.0133	CbGeAlD
Nilotinib—HCK—liver—gallbladder cancer	0.00366	0.0132	CbGeAlD
Nilotinib—ABL2—liver—gallbladder cancer	0.00364	0.0131	CbGeAlD
Nilotinib—KIT—epithelium—gallbladder cancer	0.00356	0.0128	CbGeAlD
Nilotinib—PDGFRB—epithelium—gallbladder cancer	0.00347	0.0125	CbGeAlD
Nilotinib—MAP4K1—lymph node—gallbladder cancer	0.00337	0.0121	CbGeAlD
Nilotinib—CA3—liver—gallbladder cancer	0.00329	0.0118	CbGeAlD
Nilotinib—TIE1—lymph node—gallbladder cancer	0.00321	0.0115	CbGeAlD
Nilotinib—KIT—pancreas—gallbladder cancer	0.00317	0.0114	CbGeAlD
Nilotinib—PDGFRB—pancreas—gallbladder cancer	0.00309	0.0111	CbGeAlD
Nilotinib—BRAF—lymph node—gallbladder cancer	0.00308	0.0111	CbGeAlD
Nilotinib—MAPK14—liver—gallbladder cancer	0.00307	0.011	CbGeAlD
Nilotinib—FGR—liver—gallbladder cancer	0.00306	0.011	CbGeAlD
Nilotinib—LCK—liver—gallbladder cancer	0.00306	0.011	CbGeAlD
Nilotinib—EPHB3—lymph node—gallbladder cancer	0.00305	0.011	CbGeAlD
Nilotinib—CA14—liver—gallbladder cancer	0.00298	0.0107	CbGeAlD
Nilotinib—EPHB4—liver—gallbladder cancer	0.00291	0.0105	CbGeAlD
Nilotinib—CA1—pancreas—gallbladder cancer	0.0029	0.0104	CbGeAlD
Nilotinib—EPHA2—liver—gallbladder cancer	0.00285	0.0103	CbGeAlD
Nilotinib—HCK—lymph node—gallbladder cancer	0.00281	0.0101	CbGeAlD
Nilotinib—ABL2—lymph node—gallbladder cancer	0.00279	0.01	CbGeAlD
Nilotinib—TEK—liver—gallbladder cancer	0.00278	0.01	CbGeAlD
Nilotinib—ABL1—pancreas—gallbladder cancer	0.00276	0.00991	CbGeAlD
Nilotinib—EPHA4—lymph node—gallbladder cancer	0.00255	0.00917	CbGeAlD
Nilotinib—PDGFRA—liver—gallbladder cancer	0.00252	0.00906	CbGeAlD
Nilotinib—CA3—lymph node—gallbladder cancer	0.00252	0.00906	CbGeAlD
Nilotinib—UGT1A1—liver—gallbladder cancer	0.00241	0.00865	CbGeAlD
Nilotinib—MAPK14—lymph node—gallbladder cancer	0.00235	0.00846	CbGeAlD
Nilotinib—LCK—lymph node—gallbladder cancer	0.00234	0.00842	CbGeAlD
Nilotinib—FGR—lymph node—gallbladder cancer	0.00234	0.00842	CbGeAlD
Nilotinib—MAP2K5—liver—gallbladder cancer	0.00227	0.00818	CbGeAlD
Nilotinib—EPHB4—lymph node—gallbladder cancer	0.00223	0.00802	CbGeAlD
Nilotinib—CSF1R—liver—gallbladder cancer	0.00222	0.00798	CbGeAlD
Nilotinib—EPHA2—lymph node—gallbladder cancer	0.00219	0.00786	CbGeAlD
Nilotinib—TEK—lymph node—gallbladder cancer	0.00213	0.00767	CbGeAlD
Nilotinib—CA2—epithelium—gallbladder cancer	0.00211	0.00758	CbGeAlD
Nilotinib—EPHB6—lymph node—gallbladder cancer	0.00204	0.00733	CbGeAlD
Nilotinib—KIT—liver—gallbladder cancer	0.00202	0.00725	CbGeAlD
Nilotinib—PDGFRB—liver—gallbladder cancer	0.00197	0.00708	CbGeAlD
Nilotinib—PDGFRA—lymph node—gallbladder cancer	0.00193	0.00695	CbGeAlD
Nilotinib—CA2—pancreas—gallbladder cancer	0.00188	0.00675	CbGeAlD
Nilotinib—CA1—liver—gallbladder cancer	0.00184	0.00663	CbGeAlD
Nilotinib—ABL1—liver—gallbladder cancer	0.00175	0.00631	CbGeAlD
Nilotinib—MAP2K5—lymph node—gallbladder cancer	0.00174	0.00627	CbGeAlD
Nilotinib—CSF1R—lymph node—gallbladder cancer	0.0017	0.00612	CbGeAlD
Nilotinib—KIT—lymph node—gallbladder cancer	0.00155	0.00556	CbGeAlD
Nilotinib—PDGFRB—lymph node—gallbladder cancer	0.00151	0.00543	CbGeAlD
Nilotinib—CA1—lymph node—gallbladder cancer	0.00141	0.00508	CbGeAlD
Nilotinib—ABL1—lymph node—gallbladder cancer	0.00135	0.00484	CbGeAlD
Nilotinib—CA2—liver—gallbladder cancer	0.00119	0.0043	CbGeAlD
Nilotinib—CYP2C8—liver—gallbladder cancer	0.00114	0.00409	CbGeAlD
Nilotinib—ABCG2—liver—gallbladder cancer	0.00111	0.00398	CbGeAlD
Nilotinib—CA4—lymph node—gallbladder cancer	0.0011	0.00397	CbGeAlD
Nilotinib—CYP2B6—liver—gallbladder cancer	0.00102	0.00367	CbGeAlD
Nilotinib—CYP2C9—liver—gallbladder cancer	0.00101	0.00363	CbGeAlD
Nilotinib—ABCB1—epithelium—gallbladder cancer	0.000963	0.00346	CbGeAlD
Nilotinib—CA2—lymph node—gallbladder cancer	0.000916	0.00329	CbGeAlD
Nilotinib—ABCB1—pancreas—gallbladder cancer	0.000858	0.00308	CbGeAlD
Nilotinib—ABCG2—lymph node—gallbladder cancer	0.000848	0.00305	CbGeAlD
Nilotinib—CYP3A4—liver—gallbladder cancer	0.000771	0.00277	CbGeAlD
Nilotinib—CYP2D6—liver—gallbladder cancer	0.000759	0.00273	CbGeAlD
Nilotinib—ABCB1—liver—gallbladder cancer	0.000546	0.00196	CbGeAlD
Nilotinib—ABCB1—lymph node—gallbladder cancer	0.000418	0.0015	CbGeAlD
Nilotinib—LCK—Innate Immune System—BCL2—gallbladder cancer	7.93e-05	0.00011	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—NRAS—gallbladder cancer	7.91e-05	0.00011	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—HRAS—gallbladder cancer	7.87e-05	0.000109	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB4—gallbladder cancer	7.82e-05	0.000108	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—EGFR—gallbladder cancer	7.81e-05	0.000108	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—NRAS—gallbladder cancer	7.79e-05	0.000108	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—ERBB2—gallbladder cancer	7.71e-05	0.000107	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—NRAS—gallbladder cancer	7.68e-05	0.000106	CbGpPWpGaD
Nilotinib—HCK—Immune System—NRAS—gallbladder cancer	7.66e-05	0.000106	CbGpPWpGaD
Nilotinib—LCK—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	7.65e-05	0.000106	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB4—gallbladder cancer	7.64e-05	0.000106	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—NRAS—gallbladder cancer	7.53e-05	0.000104	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—HRAS—gallbladder cancer	7.52e-05	0.000104	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB3—gallbladder cancer	7.5e-05	0.000104	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—EGFR—gallbladder cancer	7.5e-05	0.000104	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—BCL2—gallbladder cancer	7.49e-05	0.000104	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB3—gallbladder cancer	7.43e-05	0.000103	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB4—gallbladder cancer	7.4e-05	0.000103	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—ERBB2—gallbladder cancer	7.4e-05	0.000103	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—EGFR—gallbladder cancer	7.39e-05	0.000102	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—EGFR—gallbladder cancer	7.38e-05	0.000102	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—KRAS—gallbladder cancer	7.37e-05	0.000102	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—EGFR—gallbladder cancer	7.34e-05	0.000102	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—NRAS—gallbladder cancer	7.31e-05	0.000101	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—ERBB2—gallbladder cancer	7.27e-05	0.000101	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB3—gallbladder cancer	7.16e-05	9.92e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—NRAS—gallbladder cancer	7.15e-05	9.91e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—NRAS—gallbladder cancer	7.12e-05	9.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—EGFR—gallbladder cancer	7.09e-05	9.83e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—KRAS—gallbladder cancer	7.08e-05	9.81e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—NRAS—gallbladder cancer	7.08e-05	9.8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—NRAS—gallbladder cancer	7.02e-05	9.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—EGFR—gallbladder cancer	7e-05	9.69e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—EGFR—gallbladder cancer	6.98e-05	9.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—KRAS—gallbladder cancer	6.98e-05	9.67e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—KRAS—gallbladder cancer	6.97e-05	9.66e-05	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—HRAS—gallbladder cancer	6.95e-05	9.63e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—NRAS—gallbladder cancer	6.95e-05	9.62e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—NRAS—gallbladder cancer	6.95e-05	9.62e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—KRAS—gallbladder cancer	6.94e-05	9.61e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—NRAS—gallbladder cancer	6.92e-05	9.59e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—NRAS—gallbladder cancer	6.87e-05	9.52e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—KRAS—gallbladder cancer	6.84e-05	9.47e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—KRAS—gallbladder cancer	6.81e-05	9.43e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—NRAS—gallbladder cancer	6.78e-05	9.39e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	6.78e-05	9.39e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB3—gallbladder cancer	6.76e-05	9.37e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—BCL2—gallbladder cancer	6.75e-05	9.35e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—KRAS—gallbladder cancer	6.7e-05	9.29e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB4—gallbladder cancer	6.67e-05	9.24e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—EGFR—gallbladder cancer	6.66e-05	9.22e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—ERBB2—gallbladder cancer	6.65e-05	9.22e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB3—gallbladder cancer	6.61e-05	9.16e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—KRAS—gallbladder cancer	6.61e-05	9.16e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—KRAS—gallbladder cancer	6.6e-05	9.14e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—ERBB2—gallbladder cancer	6.56e-05	9.09e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB4—gallbladder cancer	6.53e-05	9.05e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—EGFR—gallbladder cancer	6.52e-05	9.03e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—NRAS—gallbladder cancer	6.51e-05	9.02e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—EGFR—gallbladder cancer	6.49e-05	8.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—KRAS—gallbladder cancer	6.48e-05	8.98e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—EGFR—gallbladder cancer	6.45e-05	8.93e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB3—gallbladder cancer	6.4e-05	8.87e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	6.4e-05	8.87e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—EGFR—gallbladder cancer	6.39e-05	8.86e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—BCL2—gallbladder cancer	6.39e-05	8.85e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—EGFR—gallbladder cancer	6.33e-05	8.77e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—EGFR—gallbladder cancer	6.33e-05	8.77e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—EGFR—gallbladder cancer	6.31e-05	8.74e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—KRAS—gallbladder cancer	6.29e-05	8.71e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—HRAS—gallbladder cancer	6.27e-05	8.68e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—EGFR—gallbladder cancer	6.26e-05	8.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—ERBB2—gallbladder cancer	6.21e-05	8.6e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB4—gallbladder cancer	6.19e-05	8.58e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—EGFR—gallbladder cancer	6.18e-05	8.56e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—KRAS—gallbladder cancer	6.16e-05	8.53e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—KRAS—gallbladder cancer	6.13e-05	8.49e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—KRAS—gallbladder cancer	6.09e-05	8.44e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—gallbladder cancer	6.08e-05	8.42e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—ERBB2—gallbladder cancer	6.06e-05	8.39e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—gallbladder cancer	6.05e-05	8.38e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—KRAS—gallbladder cancer	6.04e-05	8.37e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—HRAS—gallbladder cancer	6.02e-05	8.34e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—KRAS—gallbladder cancer	5.98e-05	8.28e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—KRAS—gallbladder cancer	5.98e-05	8.28e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—KRAS—gallbladder cancer	5.96e-05	8.25e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—HRAS—gallbladder cancer	5.93e-05	8.22e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—HRAS—gallbladder cancer	5.93e-05	8.21e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—KRAS—gallbladder cancer	5.91e-05	8.19e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ERBB2—gallbladder cancer	5.9e-05	8.18e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—HRAS—gallbladder cancer	5.9e-05	8.17e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—NRAS—gallbladder cancer	5.86e-05	8.12e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—KRAS—gallbladder cancer	5.84e-05	8.09e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—HRAS—gallbladder cancer	5.81e-05	8.05e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—HRAS—gallbladder cancer	5.79e-05	8.02e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB3—gallbladder cancer	5.77e-05	7.99e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—gallbladder cancer	5.76e-05	7.98e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—BCL2—gallbladder cancer	5.76e-05	7.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ERBB2—gallbladder cancer	5.73e-05	7.94e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—HRAS—gallbladder cancer	5.7e-05	7.89e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	5.69e-05	7.88e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB3—gallbladder cancer	5.65e-05	7.82e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—BCL2—gallbladder cancer	5.64e-05	7.81e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—NRAS—gallbladder cancer	5.63e-05	7.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—HRAS—gallbladder cancer	5.62e-05	7.78e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ERBB2—gallbladder cancer	5.61e-05	7.77e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—BCL2—gallbladder cancer	5.61e-05	7.77e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—HRAS—gallbladder cancer	5.61e-05	7.77e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—KRAS—gallbladder cancer	5.61e-05	7.77e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ERBB2—gallbladder cancer	5.59e-05	7.75e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—NRAS—gallbladder cancer	5.53e-05	7.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—HRAS—gallbladder cancer	5.51e-05	7.63e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ERBB2—gallbladder cancer	5.48e-05	7.59e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ERBB2—gallbladder cancer	5.45e-05	7.55e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB4—gallbladder cancer	5.35e-05	7.42e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB3—gallbladder cancer	5.35e-05	7.42e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—HRAS—gallbladder cancer	5.34e-05	7.4e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—BCL2—gallbladder cancer	5.34e-05	7.4e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—EGFR—gallbladder cancer	5.34e-05	7.4e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—HRAS—gallbladder cancer	5.23e-05	7.25e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—HRAS—gallbladder cancer	5.21e-05	7.22e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERBB2—gallbladder cancer	5.19e-05	7.19e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—HRAS—gallbladder cancer	5.18e-05	7.17e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ERBB2—gallbladder cancer	5.16e-05	7.15e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—HRAS—gallbladder cancer	5.13e-05	7.11e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—EGFR—gallbladder cancer	5.13e-05	7.11e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—HRAS—gallbladder cancer	5.08e-05	7.04e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—HRAS—gallbladder cancer	5.08e-05	7.04e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—HRAS—gallbladder cancer	5.06e-05	7.02e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—NRAS—gallbladder cancer	5.06e-05	7.01e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—KRAS—gallbladder cancer	5.05e-05	6.99e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—EGFR—gallbladder cancer	5.04e-05	6.98e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—HRAS—gallbladder cancer	5.02e-05	6.96e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—NRAS—gallbladder cancer	4.99e-05	6.91e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—gallbladder cancer	4.98e-05	6.9e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—HRAS—gallbladder cancer	4.96e-05	6.87e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—KRAS—gallbladder cancer	4.85e-05	6.71e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—HRAS—gallbladder cancer	4.76e-05	6.6e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—KRAS—gallbladder cancer	4.76e-05	6.6e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—NRAS—gallbladder cancer	4.72e-05	6.54e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB2—gallbladder cancer	4.7e-05	6.52e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB2—gallbladder cancer	4.66e-05	6.45e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB3—gallbladder cancer	4.63e-05	6.41e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—BCL2—gallbladder cancer	4.62e-05	6.4e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—EGFR—gallbladder cancer	4.61e-05	6.39e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—NRAS—gallbladder cancer	4.61e-05	6.38e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—EGFR—gallbladder cancer	4.55e-05	6.3e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—NRAS—gallbladder cancer	4.49e-05	6.22e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB2—gallbladder cancer	4.49e-05	6.22e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—NRAS—gallbladder cancer	4.36e-05	6.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—KRAS—gallbladder cancer	4.36e-05	6.03e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—EGFR—gallbladder cancer	4.3e-05	5.96e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—KRAS—gallbladder cancer	4.29e-05	5.95e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—HRAS—gallbladder cancer	4.29e-05	5.94e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—NRAS—gallbladder cancer	4.27e-05	5.91e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—NRAS—gallbladder cancer	4.26e-05	5.9e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—gallbladder cancer	4.24e-05	5.87e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—EGFR—gallbladder cancer	4.2e-05	5.81e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—NRAS—gallbladder cancer	4.17e-05	5.77e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—NRAS—gallbladder cancer	4.15e-05	5.74e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—gallbladder cancer	4.14e-05	5.74e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—HRAS—gallbladder cancer	4.12e-05	5.71e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—EGFR—gallbladder cancer	4.09e-05	5.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—KRAS—gallbladder cancer	4.07e-05	5.63e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—HRAS—gallbladder cancer	4.05e-05	5.61e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—gallbladder cancer	4.01e-05	5.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—EGFR—gallbladder cancer	3.97e-05	5.5e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—KRAS—gallbladder cancer	3.97e-05	5.49e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—NRAS—gallbladder cancer	3.95e-05	5.47e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—NRAS—gallbladder cancer	3.93e-05	5.44e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—EGFR—gallbladder cancer	3.89e-05	5.39e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—EGFR—gallbladder cancer	3.88e-05	5.37e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—KRAS—gallbladder cancer	3.86e-05	5.35e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—EGFR—gallbladder cancer	3.8e-05	5.26e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—EGFR—gallbladder cancer	3.78e-05	5.23e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—KRAS—gallbladder cancer	3.75e-05	5.2e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—HRAS—gallbladder cancer	3.7e-05	5.13e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—KRAS—gallbladder cancer	3.67e-05	5.09e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—KRAS—gallbladder cancer	3.66e-05	5.07e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—HRAS—gallbladder cancer	3.65e-05	5.06e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—gallbladder cancer	3.62e-05	5.01e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—EGFR—gallbladder cancer	3.6e-05	4.99e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—KRAS—gallbladder cancer	3.59e-05	4.97e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—EGFR—gallbladder cancer	3.58e-05	4.96e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—NRAS—gallbladder cancer	3.58e-05	4.96e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—KRAS—gallbladder cancer	3.57e-05	4.94e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—NRAS—gallbladder cancer	3.54e-05	4.91e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—gallbladder cancer	3.54e-05	4.9e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—HRAS—gallbladder cancer	3.46e-05	4.79e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—gallbladder cancer	3.43e-05	4.76e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—NRAS—gallbladder cancer	3.41e-05	4.73e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—KRAS—gallbladder cancer	3.4e-05	4.71e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—KRAS—gallbladder cancer	3.38e-05	4.68e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—HRAS—gallbladder cancer	3.37e-05	4.67e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—gallbladder cancer	3.36e-05	4.65e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—gallbladder cancer	3.29e-05	4.55e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—gallbladder cancer	3.27e-05	4.52e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—gallbladder cancer	3.26e-05	4.52e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—gallbladder cancer	3.23e-05	4.47e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—gallbladder cancer	3.23e-05	4.47e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—gallbladder cancer	3.19e-05	4.42e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—gallbladder cancer	3.15e-05	4.37e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—gallbladder cancer	3.12e-05	4.33e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—gallbladder cancer	3.11e-05	4.31e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—gallbladder cancer	3.11e-05	4.31e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—gallbladder cancer	3.08e-05	4.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—gallbladder cancer	3.05e-05	4.23e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—gallbladder cancer	3.05e-05	4.23e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—gallbladder cancer	3.05e-05	4.22e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—gallbladder cancer	3.03e-05	4.2e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—gallbladder cancer	2.94e-05	4.07e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—gallbladder cancer	2.94e-05	4.07e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—gallbladder cancer	2.9e-05	4.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—gallbladder cancer	2.89e-05	4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—gallbladder cancer	2.87e-05	3.98e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—gallbladder cancer	2.87e-05	3.98e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—gallbladder cancer	2.78e-05	3.85e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—gallbladder cancer	2.78e-05	3.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—gallbladder cancer	2.75e-05	3.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—gallbladder cancer	2.74e-05	3.79e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—gallbladder cancer	2.71e-05	3.76e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—gallbladder cancer	2.71e-05	3.76e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—gallbladder cancer	2.69e-05	3.73e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—gallbladder cancer	2.63e-05	3.64e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—gallbladder cancer	2.62e-05	3.63e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—gallbladder cancer	2.59e-05	3.59e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—gallbladder cancer	2.55e-05	3.54e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—gallbladder cancer	2.51e-05	3.47e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—gallbladder cancer	2.5e-05	3.46e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—gallbladder cancer	2.47e-05	3.42e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—gallbladder cancer	2.45e-05	3.4e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—gallbladder cancer	2.37e-05	3.28e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—gallbladder cancer	2.36e-05	3.27e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—gallbladder cancer	2.34e-05	3.24e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—gallbladder cancer	2.33e-05	3.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—gallbladder cancer	2.32e-05	3.21e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—gallbladder cancer	2.31e-05	3.2e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—gallbladder cancer	2.23e-05	3.1e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—gallbladder cancer	2.21e-05	3.06e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—gallbladder cancer	2.2e-05	3.04e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—gallbladder cancer	2.1e-05	2.92e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—gallbladder cancer	2.06e-05	2.85e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—gallbladder cancer	2.01e-05	2.79e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—gallbladder cancer	2.01e-05	2.79e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—gallbladder cancer	1.97e-05	2.73e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—gallbladder cancer	1.95e-05	2.71e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—gallbladder cancer	1.9e-05	2.63e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—gallbladder cancer	1.87e-05	2.59e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—gallbladder cancer	1.69e-05	2.34e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—gallbladder cancer	1.62e-05	2.24e-05	CbGpPWpGaD
